Search
for
Sort by
Research 91–120 of 1000+
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- PRIDE syndrome associated with panitumumab treatment – case report and literature review
- Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
- When bugs and drugs conspire: driving acneiform skin toxicity
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- 1338 Epidermal growth factor receptor protects from immune privilege collapse and scarring hair follicle destruction
- Cetuximab Induced Hidrocystomas: A Case Report
- The relevance of collagen XVII expression in epidermal differentiation and proliferation
- Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Pathogenesis and management of TRPV3-related Olmsted syndrome
- ISID1338 - Epidermal growth factor receptor protects from immune privilege collapse and scarring hair follicle destruction
- PRIDE syndrome with lumbosacral hypertrichosis
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Proceedings of the Heinz Maurer-Symposium “Review and Preview in Science for Healthy Skin” June 28th 2014, Jakobsberg, Boppard, Germany
- The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth? - eScholarship
- A Story About Hair
- Treatment of acne with intermittent isotretinoin, cohort study
- 645 MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
- The control of hair growth: An overview
- Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Gefitinib-induced hair alterations: Figure 1
- 546 Epidermal growth factor receptor as a key regulator of the immune privilege
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- Recurrent inverse necrotizing infundibular crystalline folliculitis
- Injury suppresses Ras cell competitive advantage through enhanced wild-type cell proliferation
- An unusual terminal hair growth on the nose tip associated with gefitinib therapy
- Prevention of erlotinib-induced folliculitis with doxycycline